What does Unjha Formul. do?

Unjha Formulations Ltd is a micro-cap pharmaceutical company focused on manufacturing Isabgol (Psyllium) formulations, with a market cap of Rs 10 Cr and reported net sales of 2 Cr for the quarter ending March 2025. The company has a P/E ratio of 11.00 and a return on equity of 12.74%.

Overview:<BR>Unjha Formulations Ltd is a micro-cap company in the Pharmaceuticals & Biotechnology industry, specializing in the manufacturing of pharmaceutical formulations, particularly Isabgol (Psyllium) formulations.<BR><BR>History:<BR>Established in June 1987 as a partnership firm, Unjha Formulations Ltd has maintained its focus on pharmaceutical formulations. The latest reported quarterly results indicate net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>- Net Sales: 2 Cr (Quarterly Results - Mar 2025)<BR>- Net Profit: 0 Cr (Quarterly Results - Mar 2025)<BR>- Market-cap: Rs 10 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: 11.00<BR>- Industry P/E: 35<BR>- Dividend Yield: 0.00%<BR>- Debt-Equity: -0.20<BR>- Return on Equity: 12.74%<BR>- Price to Book: 3.39<BR><BR>Contact Details:<BR>Address: Khali Char Rasta, State Highway Ta Sidhpur Patan Gujarat : 384151<BR>Tel: 91-2767-282395<BR>Email: info@unjhaformulations.com<BR>Website: http://www.unjhaformulations.com

Has Unjha Formul. declared dividend?

No Dividend History Available

Who are the peers of the Unjha Formul.?

Unjha Formul.'s peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Vivanza Biosci, Cian Healthcare, Beryl Drugs, and Ortin Global. Management risk is average for Unjha Formul., with below-average growth and a 1-year return of -9.60%.

Peers: The peers of Unjha Formul. are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Vivanza Biosci., Cian Healthcare, Beryl Drugs, Ortin Global.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Cipla, Divi's Lab., and Dr Reddy's Labs, while Average management risk is found at Unjha Formul. Below Average management risk is seen at Vivanza Biosci., Cian Healthcare, Beryl Drugs, and Ortin Global. Growth is Excellent for Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Unjha Formul. and Torrent Pharma show Below Average growth, and the rest exhibit Below Average growth as well. Capital Structure is Excellent at Sun Pharma.Inds. and Divi's Lab., Good at Torrent Pharma and Unjha Formul., and Below Average at Vivanza Biosci., Cian Healthcare, Beryl Drugs, Ortin Global.<BR><BR>Return Snapshot: Divi's Lab. has the highest 1-year return at 51.69%, while Vivanza Biosci. has the lowest at -60.94%. Unjha Formul.'s 1-year return is -9.60%, which is significantly better than Vivanza Biosci. but worse than Divi's Lab. Additionally, the six-month return is negative for Unjha Formul., Vivanza Biosci., Cian Healthcare, Beryl Drugs, Ortin Global, and Adline Chem Lab.

What is the technical trend for Unjha Formul.?

As of June 6, 2025, Unjha Formul's technical trend is neutral with mixed signals, showing a sideways movement influenced by mildly bullish weekly indicators and mildly bearish monthly indicators.

As of 6 June 2025, the technical trend for Unjha Formul has changed from mildly bearish to sideways. The current stance is neutral, with mixed signals across different time frames. The weekly MACD is mildly bullish, while the monthly MACD is mildly bearish. The weekly RSI indicates bullish momentum, but the monthly RSI shows no signal. Bollinger Bands are bullish in both weekly and monthly views, suggesting potential upward movement. However, daily moving averages are mildly bearish, indicating short-term weakness. The KST shows a mildly bullish trend weekly but is mildly bearish monthly. Dow Theory indicates no trend in both weekly and monthly assessments. Overall, the indicators reflect a sideways movement with no strong bullish or bearish bias at this time.

Who are in the management team of Unjha Formul.?

As of March 2023, the management team of Unjha Formul includes Krutiben M Patel (Managing Director), Jashodaben S Patel (Chairman), and several independent directors: Hasmukh C Chavda, Jitendrakumar Limbachiya, and Mustufa Najmuddin, along with Jigar Ray (Company Secretary) and Esham Patel (Additional Director).

As of March 2023, the management team of Unjha Formul includes the following individuals:<BR><BR>1. Krutiben M Patel - Managing Director<BR>2. Hasmukh C Chavda - Independent Director<BR>3. Jashodaben S Patel - Chairman (Non-Executive)<BR>4. Jitendrakumar Parshottamdas Limbachiya - Independent Director<BR>5. Jigar Ray - Company Secretary & Compliance Officer<BR>6. Mustufa Najmuddin - Independent Director<BR>7. Esham Patel - Additional Director<BR><BR>These individuals play key roles in the governance and operational management of the company.

Who are the top shareholders of the Unjha Formul.?

The top shareholder of Unjha Formul is Jashodaben Shambhubhai Patel with 16.51%, followed by public shareholder Esha Mayank Patel at 1.6%. Individual investors collectively hold 56.1%, with no pledged promoter holdings or participation from mutual funds or foreign institutional investors.

The top shareholders of Unjha Formul include Jashodaben Shambhubhai Patel, who holds the highest stake at 16.51%. Following her, the highest public shareholder is Esha Mayank Patel with a holding of 1.6%. Additionally, individual investors collectively hold a significant portion of the company at 56.1%. There are no pledged promoter holdings, and the company does not have any mutual fund or foreign institutional investor participation.

How big is Unjha Formul.?

As of 24th July, Unjha Formulations Ltd has a market capitalization of 11.00 Cr, with net sales of 13.86 Cr and a net profit of 0.40 Cr over the latest four quarters.

As of 24th July, Unjha Formulations Ltd has a market capitalization of 11.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Unjha Formulations reported Net Sales of 13.86 Cr and a Net Profit of 0.40 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with Shareholder's Funds amounting to 3.14 Cr and Total Assets of 4.56 Cr.

Are Unjha Formul. latest results good or bad?

Unjha Formulations' latest results show mixed performance: while quarterly net sales increased by 52.32% from the previous quarter, they declined by 28.64% year-on-year. The company has seen a significant profit increase, but overall sentiment remains cautious with a 'Strong Sell' rating due to ongoing challenges.

Unjha Formulations' latest results present a mixed picture. While there has been a notable improvement in quarterly growth metrics, the overall performance remains concerning due to a significant decline in year-on-year net sales.<BR><BR>For the quarter ending June 2025, net sales were reported at Rs 5.98 crore, which reflects a sharp decline of 28.64% compared to the same period last year. However, on a quarter-over-quarter basis, net sales showed a positive growth of 52.32%, indicating some recovery from the previous quarter's performance.<BR><BR>Additionally, the standalone net profit saw a remarkable increase of 195.12% from the previous quarter, which is a positive sign, although it is essential to note that the previous quarter had a very low base due to a substantial loss.<BR><BR>Despite these improvements, the overall sentiment is cautious, as indicated by the 'Strong Sell' rating from MarketsMOJO. Stakeholders will likely be watching closely to see if these trends can be sustained in the upcoming quarters. In summary, while there are signs of recovery in the short term, the long-term outlook appears challenging due to the significant year-on-year decline in sales.

When is the next results date for Unjha Formul.?

Unjha Formul. will declare its results on 10 November 2025.

Unjha Formul. will declare its results on 10 November 2025.

Is Unjha Formul. overvalued or undervalued?

As of November 12, 2025, Unjha Formul. is considered undervalued with a PE ratio of 11.08 and a PEG ratio of 0.40, significantly outperforming peers like Sun Pharma. and Divi's Lab., and demonstrating strong long-term returns of 149.21% over three years and 250.28% over five years, despite recent underperformance year-to-date.

As of 12 November 2025, the valuation grade for Unjha Formul. has moved from very expensive to very attractive, indicating a significant shift in its perceived value. The company is currently considered undervalued, with a PE ratio of 11.08, an EV to EBIT of 10.66, and an impressive ROE of 32.48%. <BR><BR>In comparison to its peers, Unjha Formul. stands out with a PEG ratio of 0.40, while Sun Pharma. Inds. has a PE of 35.94 and Divi's Lab. shows a staggering PE of 69.64, both categorized as expensive. The attractive valuation of Unjha Formul. is further supported by its strong performance metrics, particularly its ROCE of 16.80%. Despite recent underperformance in the YTD return compared to the Sensex, the long-term performance over 3 years and 5 years shows a remarkable return of 149.21% and 250.28%, respectively, reinforcing the attractiveness of its current valuation.

How has been the historical performance of Unjha Formul.?

Unjha Formul's historical performance has shown fluctuations in net sales and profits, with net sales decreasing to 13.86 Cr in March 2025 from 18.50 Cr in March 2024, but profit after tax increased to 0.41 Cr. Despite volatility, the company improved its profitability metrics and shareholder equity during this period.

Answer:<BR>The historical performance of Unjha Formul shows fluctuations in key financial metrics over the years, with notable changes in net sales, operating profit, and profit after tax.<BR><BR>Breakdown:<BR>Unjha Formul's net sales have varied significantly, reaching 13.86 Cr in March 2025, down from 18.50 Cr in March 2024, but up from 13.15 Cr in March 2023. The total operating income followed a similar trend, with a peak in March 2024. The raw material costs decreased to 11.32 Cr in March 2025 from 15.55 Cr in March 2024, contributing to a total expenditure of 13.35 Cr in March 2025, down from 17.92 Cr the previous year. Operating profit, excluding other income, improved to 0.51 Cr in March 2025, while profit before tax rose to 0.52 Cr, leading to a profit after tax of 0.41 Cr, an increase from 0.28 Cr in both March 2024 and March 2023. The company's total assets decreased to 4.56 Cr in March 2025 from 4.93 Cr in March 2024, with total liabilities also declining to 4.56 Cr. The book value per share increased to 7.01 in March 2025, reflecting a positive trend in shareholder equity, which rose to 3.14 Cr from 2.73 Cr in March 2024. Overall, while Unjha Formul experienced some volatility in sales and profits, it showed improvements in profitability metrics and shareholder value over the observed period.

Should I buy, sell or hold Unjha Formul.?

Which are the latest news on Unjha Formul.?

Why is Unjha Formul. falling/rising?

As of 04-Dec, Unjha Formulations Ltd's stock price is currently at 25.20, reflecting a 1.98% increase today and a 9.57% rise over the past month. However, it has declined 17.08% year-to-date and shows reduced investor participation, indicating a mixed outlook despite the recent price increase.

As of 04-Dec, Unjha Formulations Ltd's stock price is rising, currently at 25.20, with a change of 0.49 (1.98%) upwards. This positive movement can be attributed to its performance today, where it outperformed the sector by 1.69%. Additionally, the stock has shown a significant increase over the past month, with a rise of 9.57%, compared to a modest 2.16% increase in the Sensex. <BR><BR>However, it is important to note that despite the current rise, the stock has experienced a decline of 17.08% year-to-date and a 20.03% drop over the past year. The stock is also trading higher than its 50-day, 100-day, and 200-day moving averages, indicating a potential upward trend in the short term. <BR><BR>On the downside, there has been a notable decrease in investor participation, with delivery volume on December 3 falling by 86.01% against the 5-day average. This decline in trading activity could suggest caution among investors despite the current price increase. Overall, while the stock is experiencing a rise today, its longer-term performance and reduced investor participation present a mixed outlook.